CL2009000918A1 - Uso de una asociacion de dronedarona o una sal farmaceuticamente aceptable con al menos un diuretico para preparar medicamentos util para prevenir hospitalizaciones cardiovasculares y/o la mortalidad en pacientes con antecedentes de fibrilacion auricular o aleteo auricular. - Google Patents

Uso de una asociacion de dronedarona o una sal farmaceuticamente aceptable con al menos un diuretico para preparar medicamentos util para prevenir hospitalizaciones cardiovasculares y/o la mortalidad en pacientes con antecedentes de fibrilacion auricular o aleteo auricular.

Info

Publication number
CL2009000918A1
CL2009000918A1 CL2009000918A CL2009000918A CL2009000918A1 CL 2009000918 A1 CL2009000918 A1 CL 2009000918A1 CL 2009000918 A CL2009000918 A CL 2009000918A CL 2009000918 A CL2009000918 A CL 2009000918A CL 2009000918 A1 CL2009000918 A1 CL 2009000918A1
Authority
CL
Chile
Prior art keywords
dronedarone
diuretic
association
mortality
history
Prior art date
Application number
CL2009000918A
Other languages
English (en)
Inventor
David Van Eickels Martin Radzik
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39684441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2009000918A1 publication Critical patent/CL2009000918A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Utilización de una asociación de dronedarona con al menos un diurético para preparar medicamentos para prevenir hospitalizaciones cardiovasculares y/o la mortalidad cardiovascular; asociación de dronedarona con al menos un diurético.
CL2009000918A 2008-04-17 2009-04-16 Uso de una asociacion de dronedarona o una sal farmaceuticamente aceptable con al menos un diuretico para preparar medicamentos util para prevenir hospitalizaciones cardiovasculares y/o la mortalidad en pacientes con antecedentes de fibrilacion auricular o aleteo auricular. CL2009000918A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0802128A FR2930149B1 (fr) 2008-04-17 2008-04-17 Association de dronedarone avec au moins un diuretique, son application en therapeutique
US4599908P 2008-04-18 2008-04-18

Publications (1)

Publication Number Publication Date
CL2009000918A1 true CL2009000918A1 (es) 2010-06-11

Family

ID=39684441

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000918A CL2009000918A1 (es) 2008-04-17 2009-04-16 Uso de una asociacion de dronedarona o una sal farmaceuticamente aceptable con al menos un diuretico para preparar medicamentos util para prevenir hospitalizaciones cardiovasculares y/o la mortalidad en pacientes con antecedentes de fibrilacion auricular o aleteo auricular.

Country Status (26)

Country Link
US (1) US20110136899A1 (es)
EP (1) EP2280700A2 (es)
JP (1) JP2011517694A (es)
KR (1) KR20110005245A (es)
CN (1) CN102065856A (es)
AR (1) AR071326A1 (es)
AU (1) AU2009241966A1 (es)
BR (1) BRPI0910559A2 (es)
CA (1) CA2721560A1 (es)
CL (1) CL2009000918A1 (es)
CO (1) CO6300842A2 (es)
CR (1) CR11735A (es)
DO (1) DOP2010000308A (es)
EA (1) EA201071203A1 (es)
EC (1) ECSP10010552A (es)
FR (1) FR2930149B1 (es)
IL (1) IL208749A0 (es)
MA (1) MA32355B1 (es)
MX (1) MX2010011401A (es)
NI (1) NI201000171A (es)
PE (1) PE20091808A1 (es)
SV (1) SV2010003702A (es)
TW (1) TW200951117A (es)
UY (1) UY31772A (es)
WO (1) WO2009133310A2 (es)
ZA (1) ZA201007390B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072950A1 (es) 2008-04-17 2010-10-06 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
US4988513A (en) * 1990-01-09 1991-01-29 Monsanto Company Method of treating hypokalemia
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US6411840B1 (en) * 1999-11-16 2002-06-25 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation
FR2803846B1 (fr) * 2000-01-17 2002-04-05 Clariant France Sa 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation
FR2817864B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese
FR2817865B1 (fr) * 2000-12-11 2005-02-18 Sanofi Synthelabo Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
DE60117857D1 (de) * 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US20030229007A1 (en) * 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
DE10237819A1 (de) * 2002-08-19 2004-03-04 Bayer Ag 5-Nitrobenzofurane
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20060093673A1 (en) * 2003-06-27 2006-05-04 Coury Arthur J Controlled release of anti-arrhythmic agents
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7772232B2 (en) * 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US20070248564A1 (en) * 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
US20090076137A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dronedarone
AR072950A1 (es) * 2008-04-17 2010-10-06 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
EP2133075A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
EP2153830A1 (en) * 2008-08-07 2010-02-17 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) * 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Also Published As

Publication number Publication date
CO6300842A2 (es) 2011-07-21
WO2009133310A2 (fr) 2009-11-05
ZA201007390B (en) 2012-01-25
PE20091808A1 (es) 2009-12-03
CR11735A (es) 2010-11-22
MA32355B1 (fr) 2011-06-01
JP2011517694A (ja) 2011-06-16
IL208749A0 (en) 2010-12-30
NI201000171A (es) 2012-01-23
US20110136899A1 (en) 2011-06-09
WO2009133310A3 (fr) 2009-12-23
AU2009241966A1 (en) 2009-11-05
CN102065856A (zh) 2011-05-18
MX2010011401A (es) 2011-03-02
ECSP10010552A (es) 2010-11-30
FR2930149B1 (fr) 2011-02-18
FR2930149A1 (fr) 2009-10-23
EA201071203A1 (ru) 2011-06-30
BRPI0910559A2 (pt) 2015-09-22
TW200951117A (en) 2009-12-16
KR20110005245A (ko) 2011-01-17
CA2721560A1 (fr) 2009-11-05
EP2280700A2 (fr) 2011-02-09
SV2010003702A (es) 2011-03-04
UY31772A (es) 2009-12-14
AR071326A1 (es) 2010-06-09
DOP2010000308A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
CL2010001422A1 (es) Uso de dronedarona para la preparacion de un medicamento util en la prevencion de la fibrilacion/aleteo auricular permanente
NO2018015I1 (no) 2-{4-[N-(5,6-difenylpyrazin-2-yl)-N-isopropylamino]butyloksy}-N-(metylsulfonyl)acetamid
BRPI1010957A2 (pt) variantes de celulase com expressão, atividade e/ou estabilidade aprimorada e uso das mesmas.
MX2010011414A (es) Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad.
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BR112012003792A2 (pt) gel tópico, e, uso do gel tópico.
WO2008116024A3 (en) Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
BRPI0914863A2 (pt) formulação tópica estável, e, uso da mesma
BR112015006790A2 (pt) composição de cetoprofeno tópico
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2009000918A1 (es) Uso de una asociacion de dronedarona o una sal farmaceuticamente aceptable con al menos un diuretico para preparar medicamentos util para prevenir hospitalizaciones cardiovasculares y/o la mortalidad en pacientes con antecedentes de fibrilacion auricular o aleteo auricular.
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
CL2009000919A1 (es) Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.
CL2010001421A1 (es) Uso de dronedarona en la preparacion de medicamentos utiles para la prevencion de fibrilacion o aleteo auricular persistentes.
BRPI0912671A2 (pt) peptídeos, peptidomiméticos e derivados dos mesmos, a fabricação dos mesmos, bem como seu uso para preparar uma composição farmacêutica terapeuticamente e/ou preventivamente ativa
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
AR080933A1 (es) Tratamiento de esclerosis multiple con masitinib
UY33381A (es) Dronedarona para prevencion de la hospitalizacion cardiovascular por fibrilación auricular
CL2012003065A1 (es) Combinación farmacéutica que comprende ibuprofeno y l-arginina en una proporción en peso de ibuprofeno/l-arginina entre 1.6 y 5.6, con excepción del valor 1.97; composición farmacéutica sólida que contiene a dicha combinación; y su uso en el tratamiento del dolor, inflamación y/o fiebre.
AR084975A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de la hospitalizacion cardiovascular o de la mortalidad en pacientes con fibrilacion auricular aislada
Chien et al. Retraction: Controlling Web Services and 802.11 Mesh Networks
吴冬梅 A Study of Nonverbal Pragmatic Failure: Forms, Causes, and Avoiding Strategies
CO6260064A2 (es) Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
Zhao et al. Retraction: Evaluating Gigabit Switches Using Perfect Communication
刘娜 Potential increase of CSR in China with modification of the current type of surgery